Delayed
Hong Kong S.E.
04:08:06 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
6.17
HKD
|
-2.06%
|
|
-1.75%
|
-45.30%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,947
|
4,755
|
3,213
|
1,789
|
-
|
-
|
Enterprise Value (EV)
1 |
1,834
|
3,816
|
2,809
|
1,336
|
1,271
|
1,112
|
P/E ratio
|
-
|
66
x
|
205
x
|
20.4
x
|
14.3
x
|
11.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.7
x
|
12
x
|
6.78
x
|
3.15
x
|
2.56
x
|
2.09
x
|
EV / Revenue
|
6.04
x
|
9.65
x
|
5.93
x
|
2.35
x
|
1.82
x
|
1.3
x
|
EV / EBITDA
|
55.7
x
|
41.7
x
|
39.4
x
|
12.3
x
|
8.04
x
|
5.62
x
|
EV / FCF
|
-
|
-34,024,860
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
2.44
x
|
3.73
x
|
2.38
x
|
1.24
x
|
1.14
x
|
1.04
x
|
Nbr of stocks (in thousands)
|
313,389
|
313,389
|
313,389
|
313,389
|
-
|
-
|
Reference price
2 |
9.403
|
15.17
|
10.25
|
5.710
|
5.710
|
5.710
|
Announcement Date
|
3/29/22
|
3/23/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
303.8
|
395.5
|
473.8
|
567.4
|
698.6
|
857.5
|
EBITDA
1 |
32.92
|
91.52
|
71.27
|
108.9
|
158.2
|
198.1
|
EBIT
1 |
20.52
|
72.08
|
25.01
|
76.6
|
125.7
|
165.5
|
Operating Margin
|
6.75%
|
18.22%
|
5.28%
|
13.5%
|
18%
|
19.3%
|
Earnings before Tax (EBT)
1 |
-
|
70.32
|
14.45
|
86.71
|
137.1
|
177.8
|
Net income
1 |
-
|
70.14
|
14.49
|
84.98
|
120.7
|
151.2
|
Net margin
|
-
|
17.73%
|
3.06%
|
14.98%
|
17.27%
|
17.63%
|
EPS
2 |
-
|
0.2300
|
0.0500
|
0.2800
|
0.4000
|
0.5000
|
Free Cash Flow
|
-
|
-112.2
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-28.36%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
3/23/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,113
|
939
|
404
|
453
|
518
|
677
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-112
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-17.1%
|
5.65%
|
1.13%
|
6.35%
|
8.37%
|
9.58%
|
ROA (Net income/ Total Assets)
|
-
|
5.16%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
1,359
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.850
|
4.070
|
4.310
|
4.590
|
4.990
|
5.490
|
Cash Flow per Share
|
-
|
-0.2300
|
-
|
-
|
-
|
-
|
Capex
|
-
|
43.4
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
10.97%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
3/23/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
5.71
CNY Average target price
9.773
CNY Spread / Average Target +71.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.30% | 252M | | +73.27% | 12.36B | | -21.89% | 7.83B | | +14.67% | 7.21B | | +4.77% | 5.97B | | +11.77% | 5.14B | | +29.65% | 4.43B | | -19.23% | 3.9B | | -42.48% | 2.2B | | +1.24% | 2.02B |
Medical Equipment
|